(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
Disclosed are (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
1. A compound selected from
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
3. A method of treating pain comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
4. The method according to claim 3 , wherein the pain is neuropathic pain.
5. The method according to claim 3 , wherein the pain is selected from peripheral neuropathic pain, pain associated with diabetic peripheral neuropathy, pain associated with lumbosacral radiculopathy and pain associated with post herpetic neuralgia.